Clinical trial
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or…
NCT00004688 · Emory University, Other · Completed
Key facts
| NCT number | NCT00004688 |
|---|---|
| Title | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms |
| Lead sponsor | Emory University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Gliomas, Glioblastoma Multiforme, Recurrent Brain Tumor |
| Intervention type | Drug |
| Interventions | carmustine, mercaptopurine, streptozocin |
| Enrollment | 35 |
| Start date | Aug 1, 1996 |
| Completion | Jul 1, 1998 |
| First posted | Feb 25, 2000 |
| Last update posted | Mar 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: